Concepedia

Jeewoong Son

JS

Statistics

Publications

4

Citations

204

H-Index

4

Active since

2014

Affiliations

Hanmi Pharmaceutical (South Korea)(Current)

Samsung Medical Center

Sungkyunkwan University

National Cancer Center

The Catholic University of Korea Seoul St. Mary's Hospital

Jeewoong Son is an author at Hanmi Pharmaceutical (South Korea) specializing in oncology, egfr inhibition, and targeted cancer therapy.

Publications per year

2014–2016

4

Publications

4

Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).

Dong‐Wan Kim, Jin Hyoung Kang, Keunchil Park et al. · Journal of Clinical Oncology · 2014 · 70 citations

, , +16

Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

Keunchil Park, Jong-Seok Lee, Ki Hyeong Lee et al. · Journal of Clinical Oncology · 2015 · 50 citations

, , +17

Abstract LB-100: Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor

Kwang‐Ok Lee, Mi Young, Mi‐Ra Kim et al. · Cancer Research · 2014 · 42 citations

, , +15

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

Keunchil Park, Jong-Seok Lee, Ki Hyeong Lee et al. · Journal of Clinical Oncology · 2016 · 42 citations

, , +15

1–4 of 4